Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
91.76(c) 91.53(c) 90.87(c) 90.91(c) 90.2(c) Last
2 630 319 3 703 564 3 994 907 5 777 305 3 052 422 Volume
-0.18% -0.25% -0.72% +0.04% -0.78% Change
More quotes
Financials (USD)
Sales 2019 17 084 M
EBIT 2019 9 778 M
Net income 2019 6 598 M
Debt 2019 1 600 M
Yield 2019 -
Sales 2020 19 183 M
EBIT 2020 11 103 M
Net income 2020 7 552 M
Finance 2020 5 243 M
Yield 2020 -
P/E ratio 2019 10,4x
P/E ratio 2020 8,72x
EV / Sales2019 3,82x
EV / Sales2020 3,04x
Capitalization 63 614 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
07/19CELGENE : Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
DJ
07/19CELGENE : FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Ass..
BU
07/16ZYMEWORKS : Says Celgene Selects Lead Oncology Therapeutic Candidate Under Colla..
DJ
07/01BRISTOL-MYERS SQUIBB COMPANY : Announces Extension of the Expiration Date for Ex..
AQ
06/26Facing Challenges, Firms Seek Deals -- WSJ
DJ
06/25GLOBAL MARKETS LIVE : AbbVie, Bristol-Myers Squibb, Linde, Amazon…
06/25CELGENE : Deal Faces Antitrust Delays
DJ
06/24BRISTOL MYERS SQUIBB : Myers, Celgene Shares Both Lower as Merger Faces Delays
DJ
06/24BRISTOL MYERS SQUIBB : Antitrust Concerns Delay Bristol-Myers' $74 Billion Merge..
DJ
06/24Bristol-Myers' Celgene Deal Can Still Be a Winner -- Heard on the Street
DJ
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Stock Trading Strategies
CELGENE CORPORATION - 03/28
In an accumulation phase
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
05:45aJOHNSON & JOHNSON : Faces Key Test in Defense Against Talc-Safety Lawsuits
DJ
07/19ALLERGAN : Form 8.3 -
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
07/19BAYER : Syngenta profits hit by U.S./China trade wars, bad weather
RE
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 99,60  $
Last Close Price 90,20  $
Spread / Highest target 33,0%
Spread / Average Target 10,4%
Spread / Lowest Target -6,87%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION41.85%63 614
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING LTD.11.42%230 263
ROCHE HOLDING13.37%230 263
NOVARTIS24.46%216 273